Market closed
Rhythm Pharmaceuticals/$RYTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Ticker
$RYTM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
283
Website
RYTM Metrics
BasicAdvanced
$4B
-
-$4.34
2.30
-
Price and volume
Market cap
$4B
Beta
2.3
52-week high
$65.17
52-week low
$35.17
Average daily volume
839K
Financial strength
Current ratio
3.239
Quick ratio
2.935
Long term debt to equity
68.191
Total debt to equity
68.191
Interest coverage (TTM)
-12.89%
Management effectiveness
Return on assets (TTM)
-45.78%
Return on equity (TTM)
-155.91%
Valuation
Price to revenue (TTM)
29.887
Price to book
183.07
Price to tangible book (TTM)
255.74
Price to free cash flow (TTM)
-25.192
Growth
Revenue change (TTM)
68.06%
Earnings per share change (TTM)
35.46%
3-year revenue growth (CAGR)
245.54%
3-year earnings per share growth (CAGR)
45.66%
What the Analysts think about RYTM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
RYTM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RYTM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RYTM News
AllArticlesVideos
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Seeking Alpha·3 weeks ago
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Reuters·3 weeks ago
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $4B as of April 28, 2025.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of April 28, 2025.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.